|
Contraindications
Pregnancy and lactation; carcinoma of prostate or breast in men, hypercalcaemia, hypercalciuria, porphyria, severe hepatic impairment.
|
|
Special Precautions
Patients with cardiac, renal or hepatic disease, epilepsy or DM. Children, elderly. Monitor liver function, haematocrit and haemoglobin concentrations. Not recommended for treatment of hereditary angioedema in premenopausal women.
|
|
Adverse Reactions
Peliosis hepatis, premature epiphyseal closure, cholestatic jaundice, virilism, impotence, priapism, testicular atrophy, gynaecomastia, prostatic hyperplasia, decreased libido, hirsutism, menstrual irregularities; oedema, acne.
Potentially Fatal: Hepatic necrosis, hepatocellular carcinoma. |
|
Drug Interactions
Enhances activity of insulin, sulfonylureas, levothyroxine and anticoagulants e.g. warfarin. May cause resistance to the effects of neuromuscular blockers.
|
|
CIMS Class
|
|
ATC Classification
A14AA02 - stanozolol ; Belongs to the class of androstan derivative anabolic steroids used as systemic anabolic agents.
|
Sign Out
